Undiscounted benefits | Discounted benefits | ||||||
---|---|---|---|---|---|---|---|
Reduction in prevalence | Number of cases averteda | Potential cost savingsb | Net benefits (costs, AUD)c | Incremental cost-effectiveness ratio (ICER, AUD)d | Potential cost savingsb | Net benefits (costs, AUD)c | Incremental cost-effectiveness ratio (ICER, AUD)d |
10.0% | 110 | $330,000,000 | $290,500,000 | -$2,640,909 | $212,740,000 | $173,240,000 | -$1,574,909 |
6.0% | 66 | $198,000,000 | $158,500,000 | -$2,401,515 | $127,644,000 | $88,144,000 | -$1,335,515 |
5.0% | 55 | $165,000,000 | $125,500,000 | -$2,281,818 | $106,370,000 | $66,870,000 | -$1,215,818 |
4.0% | 44 | $132,000,000 | $92,500,000 | -$2,102,273 | $85,096,000 | $45,596,000 | -$1,036,273 |
3.0% | 33 | $99,000,000 | $59,500,000 | -$1,803,030 | $63,822,000 | $24,322,000 | -$737,030 |
2.0% | 22 | $66,000,000 | $26,500,000 | -$1,204,545 | $42,548,000 | $3,048,000 | -$138,545 |
1.8% | 20 | $60,000,000 | $20,500,000 | -$1,025,000 | $38,680,000 | -$820,000 | $41,000 |
1.6% | 18 | $54,000,000 | $14,500,000 | -$805,556 | $34,812,000 | -$4,688,000 | $260,444 |
1.4% | 15 | $45,000,000 | $5,500,000 | -$366,667 | $29,010,000 | -$10,490,000 | $699,333 |
1.2% | 13 | $39,000,000 | -$500,000 | $38,462 | $25,142,000 | -$14,358,000 | $1,104,462 |
1.0% | 11 | $33,000,000 | -$6,500,000 | $590,909 | $21,274,000 | -$18,226,000 | $1,656,909 |